No biomarker
|
Mucosal Melanoma
|
No biomarker
|
Mucosal Melanoma
|
toripalimab Sensitive: B - Late Trials
|
toripalimab Sensitive: B - Late Trials
|
No biomarker
|
Mucosal Melanoma
|
No biomarker
|
Mucosal Melanoma
|
ALKS 4230 Sensitive: B - Late Trials
|
ALKS 4230 Sensitive: B - Late Trials
|
BRAF mutation
|
Mucosal Melanoma
|
BRAF mutation
|
Mucosal Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
MDM4 amplification
|
Mucosal Melanoma
|
MDM4 amplification
|
Mucosal Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
MDM4 amplification
|
Mucosal Melanoma
|
MDM4 amplification
|
Mucosal Melanoma
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
MDM4 amplification
|
Mucosal Melanoma
|
MDM4 amplification
|
Mucosal Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
MDM4 amplification
|
Mucosal Melanoma
|
MDM4 amplification
|
Mucosal Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
NRAS mutation
|
Mucosal Melanoma
|
NRAS mutation
|
Mucosal Melanoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
BRAF mutation
|
Mucosal Melanoma
|
BRAF mutation
|
Mucosal Melanoma
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
NRAS mutation
|
Mucosal Melanoma
|
NRAS mutation
|
Mucosal Melanoma
|
cisplatin + temozolomide Sensitive: C3 – Early Trials
|
cisplatin + temozolomide Sensitive: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
BRAF mutation
|
Mucosal Melanoma
|
BRAF mutation
|
Mucosal Melanoma
|
cisplatin + temozolomide Sensitive: C3 – Early Trials
|
cisplatin + temozolomide Sensitive: C3 – Early Trials
|
NRAS mutation
|
Mucosal Melanoma
|
NRAS mutation
|
Mucosal Melanoma
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Mucosal Melanoma
|
PD-L1 expression
|
Mucosal Melanoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
KIT L576P
|
Mucosal Melanoma
|
KIT L576P
|
Mucosal Melanoma
|
sorafenib Resistant: C4 – Case Studies
|
sorafenib Resistant: C4 – Case Studies
|
KIT L576P
|
Mucosal Melanoma
|
KIT L576P
|
Mucosal Melanoma
|
temsirolimus Resistant: C4 – Case Studies
|
temsirolimus Resistant: C4 – Case Studies
|
KIT L576P
|
Mucosal Melanoma
|
KIT L576P
|
Mucosal Melanoma
|
imatinib Resistant: C4 – Case Studies
|
imatinib Resistant: C4 – Case Studies
|